Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Accelerated BEP as first-line chemotherapy for advanced germ cell tumours
ACTRN12607000294459Phase 2Active, not recruiting
- Sponsor
- The University of Sydney
- Start
- Feb 2008
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bleomycin, etoposide, cisplatin and pegfilgrastim in germ cell tumor (GCT), sponsored by The University of Sydney. Primary endpoint: Feasibility of accelerated BEP regimen. Started Feb 2008; status: active, not recruiting.
02
Drugs
bleomycinetoposidecisplatinpegfilgrastim
03
Conditions
germ cell tumor (GCT)
Beyond the preview
Go deeper on ACTRN12607000294459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000294459.